User: Guest  Login
Title:

Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.

Document type:
Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Seufferlein, T; Uhl, W; Kornmann, M; Algül, H; Friess, H; König, A; Ghadimi, M; Gallmeier, E; Bartsch, D K; Lutz, M P; Metzger, R; Wille, K; Gerdes, B; Schimanski, C C; Graupe, F; Kunzmann, V; Klein, I; Geissler, M; Staib, L; Waldschmidt, D; Bruns, C; Wittel, U; Fichtner-Feigl, S; Daum, S; Hinke, A; Blome, L; Tannapfel, A; Kleger, A; Berger, A W; Kestler, A M R; Schuhbaur, J S; Perkhofer, L; Tempero, M; Reinacher-Schick, A C; Ettrich, T J
Abstract:
BACKGROUND: Data on perioperative chemotherapy in resectable pancreatic ductal adenocarcinoma (rPDAC) are limited. NEONAX examined perioperative or adjuvant chemotherapy with gemcitabine plus nab-paclitaxel in rPDAC (National Comprehensive Cancer Network criteria). PATIENTS AND METHODS: NEONAX is a prospective, randomized phase II trial with two independent experimental arms. One hundred twenty-seven rPDAC patients in 22 German centers were randomized 1 : 1 to perioperative (two pre-operative an...     »
Journal title abbreviation:
Ann Oncol
Year:
2023
Journal volume:
34
Journal issue:
1
Pages contribution:
91-100
Fulltext / DOI:
doi:10.1016/j.annonc.2022.09.161
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/36209981
Print-ISSN:
0923-7534
TUM Institution:
1039; 1062; 1200; Klinik und Poliklinik für Chirurgie (Prof. Friess); Lehrstuhl für Tumormetabolismus (Prof. Algül)
 BibTeX